Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

These Patients Are More Apt to Be Depressed

Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Certain subgroups of patients with hematologic malignancies are more prone to experience distress and depression, researchers concluded after conducting a study involving 246 individuals. Participants with hematologic malignancies completed the Patient Health Questionnaire 9 (PHQ-9) and Distress Thermometer (DT) prior to receiving outpatient parenteral chemotherapy. Among the results:

  • PHQ-9 score of ≥ 9 and DT score ≥ 4 pointed to a high risk of major depression and distress.
  • PHQ-9 score ≥ 9 was linked with living alone, positive PHQ-2, and high Charlson comorbidity index.
  • DT score ≥4 was linked with being married and female.

The authors noted that at-risk subgroups should be aggressively screened even in the absence of universal screening programs.

Citation:

Shreders A, Niazi S. Hodge D, et al. Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. [Published online ahead of print December 7, 2017]. Ann Hematol. doi:10.1007/s00277-017-3198-0.

This Week's Must Reads

HCV Screening Program in a Large Birth Cohort, Open Forum Infect Dis; ePub 2018 Mar 26; Cornett, et al

Do Electronic Reminders Aid in HCV Screening?, J Viral Hepat; ePub 2018 Mar 30; MacLean, et al

HCV Screening Shows Minimal Increase Overall , Cancer Epidemiol Biomarkers Prev; 2018 Apr; Kasting, et al

Improving Access to HCV Medications, J Manag Care Spec Pharm; 2018 Apr; Vu, et al

Previous HBV & Clinical Outcomes in HCV, J Viral Hepat; ePub 2018 Mar 25; Wang, et al

Must Reads in Hematologic Malignancies

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al

Tyrosine Kinase Inhibitors in Pediatric ALL, Hematology 2017; 2017 Dec 8; Silverman, et al